Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+
Qualia NAD+, Featuring ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Well Positioned To Become Category Leader In NAD+ Supplementation.
Related news for (CDXC)
- MoBot’s Stock Market Highlights – 03/05/25 10:00 AM
- MoBot’s Stock Market Highlights – 03/05/25 09:00 AM
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
- 24/7 Market News Snapshot 04 March, 2025 – ChromaDex Corporation (NASDAQ:CDXC)
- ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category